Floatz logo

Fedratinib

Essential Thrombocythemia

University of WashingtonSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Essential Thrombocythemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Thomas Jefferson University
Phase 2BB
TACROLIMUS
Thomas Jefferson University
Phase 2BB
Ruxolitinib
University of Washington
Phase 2B
Cyclophosphamide
Thomas Jefferson University
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B

View all 31 →

Same molecule, other indications

Fedratinib is also rated in:

myeloproliferative neoplasm, unclassifiableDormant
CCC
Indicative ·
53 / 100
View asset →
acquired polycythemia veraDormant
CCC
Indicative ·
53 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →